FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3152113192> ?p ?o ?g. }

• W3152113192 abstract "Backgroulld: Cisplatin at conventional doses has marginal activity in mesothe- lioma. A dose response relation for cisplatin has been suggested in other tumor types. In a phase I study on weekly cisplatin administration, 3 out of 5 patients with mesothelioma responded. Therefore a phase II study with weekly cisplatin was started with the recommended dose of 80 mg/m2/week for six weeks. Patiellts alld methods: Fourteen patients with mesothelioma stage II, with measurable lesions, were treated with cisplatin at a dose of 80 mg/m2 weekly for six weeks. Cisplatin was administered in NaCI 3 % and combined with ondansetron as antiemetic. Results: Five patients had a partial response (response rate 36%; 95% confi- dence interval 12-65%) lasting 2-8 months. Seven patients had stable disease. Ototoxicity was the most troublesome side effect: grade 2 in 3 and grade 3 in 2 pa- tients. COIlc/usiolls: cisplatin given at a higher dose intensity than in conventional schedules is active in mesothelioma. The response duration is however short possibly due to lack of effective maintenance therapy. INTRODUCTION The outlook for patients with pleural mesothelioma is still grim. Curative surgery is seldom possible and the results of radiotherapy are poor except for palliation of pain. The results of chemotherapy are far from encouraging: of those drugs tested in adequate numbers of patients only doxorubicin and cisplatin yield some activity with partial remission rates of 10-15 % (1-3). III vitro studies and studies in several tumor types in man have suggested a dose-response relationship for cisplatin (4,5). Attempts to increase cisplatin dose intensity were until recently hampered by its toxicity. Recently it was shown that administration of cisplatin in 3 % hypertonic saline in part prevents nephrotoxicity (4) while 5 HTJ-receptor antagonists more effectively prevent nausea and vomiting than the older antiemetics. In a phase 1!I1 study with a weekly cisplatin schedule, with the above mentioned supportive measures, we found that a dose of 80 mg/m2 weekly for six weeks was feasible in chemonaive patients with solid tumors (6). In that study five patients with pleural mesothelioma were treated at different dose levels and 3 of them obtained a partial response. For this reason we started a study in mesothelioma at the recommended dose." @default.
• W3152113192 created "2021-04-13" @default.
• W3152113192 creator A5006807426 @default.
• W3152113192 creator A5014774973 @default.
• W3152113192 creator A5027028957 @default.
• W3152113192 creator A5041384432 @default.
• W3152113192 date "2010-01-01" @default.
• W3152113192 modified "2023-09-24" @default.
• W3152113192 title "Weekly scheduling of cisplatin; feasibility, efficacy and perspective" @default.
• W3152113192 cites W135874484 @default.
• W3152113192 cites W1873275656 @default.
• W3152113192 cites W1901801026 @default.
• W3152113192 cites W1964574094 @default.
• W3152113192 cites W1981019686 @default.
• W3152113192 cites W1986305277 @default.
• W3152113192 cites W1998147719 @default.
• W3152113192 cites W2001837844 @default.
• W3152113192 cites W2004097714 @default.
• W3152113192 cites W2005707809 @default.
• W3152113192 cites W2009105260 @default.
• W3152113192 cites W2010954378 @default.
• W3152113192 cites W2026349090 @default.
• W3152113192 cites W2028297759 @default.
• W3152113192 cites W2033531880 @default.
• W3152113192 cites W2045181147 @default.
• W3152113192 cites W2049030259 @default.
• W3152113192 cites W2050771749 @default.
• W3152113192 cites W2083960587 @default.
• W3152113192 cites W2089670274 @default.
• W3152113192 cites W2095134667 @default.
• W3152113192 cites W2100405828 @default.
• W3152113192 cites W2112005204 @default.
• W3152113192 cites W2123605459 @default.
• W3152113192 cites W2123881536 @default.
• W3152113192 cites W2144949992 @default.
• W3152113192 cites W2167805334 @default.
• W3152113192 cites W2175530672 @default.
• W3152113192 cites W2179956917 @default.
• W3152113192 cites W2263001911 @default.
• W3152113192 cites W2412469170 @default.
• W3152113192 cites W2425455785 @default.
• W3152113192 cites W2992164348 @default.
• W3152113192 hasPublicationYear "2010" @default.
• W3152113192 type Work @default.
• W3152113192 sameAs 3152113192 @default.
• W3152113192 citedByCount "0" @default.
• W3152113192 crossrefType "journal-article" @default.
• W3152113192 hasAuthorship W3152113192A5006807426 @default.
• W3152113192 hasAuthorship W3152113192A5014774973 @default.
• W3152113192 hasAuthorship W3152113192A5027028957 @default.
• W3152113192 hasAuthorship W3152113192A5041384432 @default.
• W3152113192 hasConcept C126322002 @default.
• W3152113192 hasConcept C141071460 @default.
• W3152113192 hasConcept C142724271 @default.
• W3152113192 hasConcept C143998085 @default.
• W3152113192 hasConcept C2776694085 @default.
• W3152113192 hasConcept C2777407522 @default.
• W3152113192 hasConcept C2778239845 @default.
• W3152113192 hasConcept C2778534666 @default.
• W3152113192 hasConcept C509974204 @default.
• W3152113192 hasConcept C71924100 @default.
• W3152113192 hasConceptScore W3152113192C126322002 @default.
• W3152113192 hasConceptScore W3152113192C141071460 @default.
• W3152113192 hasConceptScore W3152113192C142724271 @default.
• W3152113192 hasConceptScore W3152113192C143998085 @default.
• W3152113192 hasConceptScore W3152113192C2776694085 @default.
• W3152113192 hasConceptScore W3152113192C2777407522 @default.
• W3152113192 hasConceptScore W3152113192C2778239845 @default.
• W3152113192 hasConceptScore W3152113192C2778534666 @default.
• W3152113192 hasConceptScore W3152113192C509974204 @default.
• W3152113192 hasConceptScore W3152113192C71924100 @default.
• W3152113192 hasLocation W31521131921 @default.
• W3152113192 hasOpenAccess W3152113192 @default.
• W3152113192 hasPrimaryLocation W31521131921 @default.
• W3152113192 isParatext "false" @default.
• W3152113192 isRetracted "false" @default.
• W3152113192 magId "3152113192" @default.
• W3152113192 workType "article" @default.